If you're looking to bolster your portfolio with some blue chip shares, you may want to look at the two listed below.
Here's why these blue chip ASX 200 shares are highly rated right now:
Image source: Getty Images
Goodman Group (ASX: GMG)
The first blue chip ASX 200 share to look at is Goodman Group. It is a leading integrated commercial and industrial property company with a portfolio of warehouses, large scale logistics facilities, and business and office parks.
Management notes that it continues to experience strong demand for its properties, which is being driven by increased intensification of use, long-term supply chain requirements, tight supply in urban infill locations and the quality of its assets.
In addition, the company has $12.7 billion of development work in progress, which is expected to underpin further solid growth over the coming years. Particularly given how the average value of its development work in progress now exceeds $3,700 per square metre, which reflects the prime location, cap rates, and expected growth in rents.
The team at Citi is very positive on Goodman. Its analysts believe the company could outperform its upgraded earnings guidance in FY 2022.
It said: "We now forecast c. 23% EPS growth in FY22 and c. 19% EPS CAGR from FY21-FY24. Our TP increases 5% on higher asset values and higher earnings. GMG remains our top pick in the sector."
Citi has a buy rating and $29.50 price target on Goodman's shares.
Healius Ltd (ASX: HLS)
Another blue chip ASX 200 share to look at is Healius. It is one of Australia's largest pathology and diagnostic imaging providers offering services via a number of brands. These include Dorevitch Pathology, QML Pathology, Laverty Pathology, and Healthcare Imaging Services.
Healius has been growing at a rapid rate over the last couple of financial years thanks to huge demand for COVID testing. And while testing volumes will inevitably decline now, the team at Morgans remain positive on the company and expects its base business to rebound as COVID headwinds ease.
It commented: "We continue to believe HLS is attractively valued and well placed, benefiting from the likely continuance of COVID PCR testing (at some level) and from the inevitable rebound in demand from a backlog in diagnosis and surgery."
Morgans has an add rating and $5.26 price target on Healius' shares.
